# Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial

Source: https://onco.cc/key-papers/paper-li-jama-oncol/  
OnCo record `paper-li-jama-oncol` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one trial page and one treatment page, indexed on Europe PMC as PubMed record 39509090 and published in JAMA Oncology; the citing pages link this DOI, which is how the record was matched.

## Summary

Importance: Equecabtagene autoleucel (eque-cel), a fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy, has exhibited potential for the treatment of relapsed or refractory multiple myeloma (RRMM), and further investigation in a larger cohort is necessary.

Objective: To evaluate whether eque-cel can benefit patients with RRMM and determine the overall response rate postinfusion.

Design, setting, and participants: The FUMANBA-1 trial was a single-arm, open-label, phase 1b/2 trial that evaluated eque-cel in adult patients with RRMM. Enrollment began in April 2020, and patients who received eque-cel will be monitored for a minimum of 15 years following the infusion. at September 2022, patients with heavily pretreated RRMM who received at least 3 prior courses of therapy from 14 centers were enrolled. Data were analyzed from April 2020 to September 2022.

Interventions: Patients received a single infusion of eque-cel at 1.0 × 106 CAR-positive T cells/kg after the lymphodepletion.

Main outcomes and measures: Efficacy was the primary objective, and safety, pharmacokinetics, and pharmacodynamics were secondary objectives.

Results: Of 103 patients who received an eque-cel infusion, 55 (53.4%) were male, and the median (range) age was 58 (39-70) years. A total of 101 patients were evaluable for efficacy. At a median (range) follow-up of 13.8 (0.4-27.2) months, the overall response rate was 96.0% (97 of 101), with 74.3% (75 of 103) achieving a complete response or better. Among the 12 patients who had prior CAR T-cell treatment, 75% (9 of 12) achieved a response. The median progression-free survival was not reached, with a 12-month progression-free survival rate of 78.8% (95% CI, 68.6-86.0). A total of 96 patients (95.0%) achieved minimal residual disease negativity at a sensitivity threshold of 10-5. Adverse events were favorable: 96 of 103 patients (93.2%) experienced cytokine release syndrome (grade 1 to 2 in 95 patients [92.3%]) and 2 (1.9%) experienced immune effector cell-associated neurotoxicity syndrome (grade 1 to 2). All cases of immune effector cell-associated neurotoxicity syndrome and 94 of 96 cases of cytokine release syndrome resolved with treatment. Additionally, only 20 patients (19.4%) developed antidrug antibodies. Cellular kinetic analysis confirmed CAR-positive T cells in all patients, with the longest duration at 735 days.

Conclusions and relevance: In this trial, eque-cel led to early, deep, and durable responses in patients with heavily pretreated RRMM with a manageable safety profile. Patients with prior CAR T-cell therapy also benefitted from eque-cel.

Trial registration: Chinese Clinical Trial Registry Identifier: ChiCTR2000033946.

Indexed on Europe PMC as PubMed record 39509090 (DOI 10.1001/jamaoncol.2024.4879). Matched by DOI alone: one trial page and one treatment page cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: JAMA Oncology
- Year: 2024
- DOI: 10.1001/jamaoncol.2024.4879
- Authors: Li C, Zhou K, Hu Y, et al.
- What it means: One trial page and one treatment page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- JAMA Oncol 2024: https://doi.org/10.1001/jamaoncol.2024.4879
- PubMed: https://pubmed.ncbi.nlm.nih.gov/39509090/
- Europe PMC: https://europepmc.org/article/MED/39509090

## Connected records

- drugs: [Equecabtagene autoleucel](https://onco.cc/drugs/equecabtagene-autoleucel/)
- trials: [FUMANBA-1](https://onco.cc/trials/fumanba-1/)
- journals: [JAMA Oncology](https://onco.cc/journals/jama-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-li-jama-oncol.json